Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Our Plans

Compare everything

See all plans, pricing and what each product includes side by side.

Plans & Subscriptions

Explore

Analyst Notes

Stocks – Q : Quality | V : Valuation | PT : Price Trend
Funds – P : Performance | Q : Quality

Top Pharma Companies in India by Market Cap

BSE Sensex 76941.61
105.83 (0.14%)

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Novartis India Ltd.	Q V+ PT	4,023 Small Cap	1,614.10 (-0.92%)	41.14	4.73	-4.06	54.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Poly Medicure Ltd.	Q V PT	17,025 Small Cap	1,666.30 (-0.79%)	50.67	5.58	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Onesource Specialty Pharma Ltd.	Q V PT	19,375 Small Cap	1,744.25 (3.23%)	406.87	3.23	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Laurus Labs Ltd.	Q V+ PT	92,623 Mid Cap	1,745.85 (1.84%)	84.7	16.43	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Ipca Laboratories Ltd.	Q V+ PT	45,090 Mid Cap	1,761.80 (-0.87%)	39.81	5.65	7.35	1.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Dr. Lal Pathlabs Ltd.	Q V PT	30,607 Small Cap	1,813.55 (-0.67%)	56.18	11.9	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Wockhardt Ltd.	Q V+ PT	30,311 Small Cap	1,855.95 (-0.51%)	142.31	6.15	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Emcure Pharmaceuticals Ltd.	Q V+ PT	36,490 Small Cap	1,945.55 (1.13%)	49.78	9.83	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,73,509 Large Cap	1,982.65 (0.46%)	41.25	5.67	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Narayana Hrudayalaya Ltd.	Q V PT	41,974 Mid Cap	2,070.80 (0.82%)	52.1	9.25	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	CORONA Remedies Ltd.	Q V+ PT	12,807 Small Cap	2,092.45 (-0.08%)	69.28	17.17	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Glenmark Pharmaceuticals Ltd.	Q V+ PT	61,928 Mid Cap	2,198.30 (0.18%)	45.47	5.89	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Lupin Ltd.	Q V PT	1,10,189 Mid Cap	2,397.60 (-0.51%)	20.66	4.92	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Gland Pharma Ltd.	Q V PT	40,049 Small Cap	2,457.95 (1.24%)	30.82	3.7	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Hester Biosciences Ltd.	Q V PT	2,151 Small Cap	2,560 (1.25%)	41.29	5.58	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	43,202 Mid Cap	2,574.05 (0.94%)	41.7	18.92	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Mankind Pharma Ltd.	Q V PT	1,05,357 Mid Cap	2,586.05 (1.37%)	51.71	6.44	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Caplin Point Laboratories Ltd.	Q V PT	19,939 Small Cap	2,613.05 (-0.39%)	31.09	5.56	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,815 Small Cap	2,651 (-2.29%)	41.8	8.47	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,882.80 (-1.22%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Acutaas Chemicals Ltd.	Q V+ PT	27,579 Small Cap	3,109.85 (-7.68%)	69.39	15.81	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Ajanta Pharma Ltd.	Q V+ PT	42,278 Mid Cap	3,346.65 (-1.10%)	40.04	9.35	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,376.85 (0.23%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,773 Small Cap	4,692 (0.30%)	41.77	23.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Pfizer Ltd.	Q V PT	21,456 Small Cap	4,706.75 (0.35%)	29.7	5.11	2.39	8.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,90,832 Large Cap	4,931.50 (-1.71%)	88.21	22.69	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,436 Small Cap	5,027.45 (-0.27%)	34.75	7.04	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Alkem Laboratories Ltd.	Q V+ PT	67,124 Mid Cap	5,628.70 (0.26%)	30.72	4.8	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Kovai Medical Center & Hospital Ltd.	Q V PT	6,411 Small Cap	5,946.75 (1.51%)	26.22	4.86	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Procter & Gamble Health Ltd.	Q V+ PT	11,257 Small Cap	6,758.40 (-0.34%)	34.43	21.46	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.25	3.23%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	592.35	2.53%
Fabtech Technologies	152.35	2.49%
Laurus Labs	1,745.85	1.84%

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,109.85	-7.68%
Senores Pharmaceutic	1,318.70	-6.57%
Suven Life Sciences	298.90	-4.11%
Wanbury	318.45	-3.85%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Ipca Laboratories informs about board meeting

Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Thursday, 13th August, 2026, to consider and take on record the standalone and consolidated unaudited financial results of the Company for the 1st quarter ended 30th June, 2026 of the financial year 2026-27. Further, with reference to the above meeting of the Board of Directors, it has already informed vide its letter dated 22nd June, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st July, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results for the 1st quarter ended 30th June, 2026 i.e., till 15th August, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Gland Pharma informs about board meeting

Gland Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026, inter alia, to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal Pathlabs - Quaterly Results

The company witnessed a 19.31% growth in the revenue at Rs. 7644.00 millions for the quarter ended June 2026 as compared to Rs. 6407.00 millions during the year-ago period.The company has announced a 28.31% increase in its profits to Rs . 1659.00 millions for the quarter ended June 2026 compared to Rs. 1293.00 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2684.00 millions from 2097.00 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	7644.00	6407.00	19.31	7644.00	6407.00	19.31	26476.00	23516.00	12.59
Other Income	299.00	263.00	13.69	299.00	263.00	13.69	1127.00	1115.00	1.08
PBIDT	2684.00	2097.00	27.99	2684.00	2097.00	27.99	8664.00	7770.00	11.51
Interest	61.00	45.00	35.56	61.00	45.00	35.56	220.00	215.00	2.33
PBDT	2623.00	2052.00	27.83	2623.00	2052.00	27.83	8143.00	7555.00	7.78
Depreciation	400.00	328.00	21.95	400.00	328.00	21.95	1541.00	1342.00	14.83
PBT	2223.00	1724.00	28.94	2223.00	1724.00	28.94	6602.00	6213.00	6.26
TAX	564.00	431.00	30.86	564.00	431.00	30.86	1520.00	1240.00	22.58
Deferred Tax	-9.00	22.00	-140.91	-9.00	22.00	-140.91	14.00	-393.00	-103.56
PAT	1659.00	1293.00	28.31	1659.00	1293.00	28.31	5082.00	4973.00	2.19
Equity	1676.00	838.00	100.00	1676.00	838.00	100.00	1676.00	836.00	100.48
PBIDTM(%)	35.11	32.73	7.28	35.11	32.73	7.28	32.72	33.04	-0.96

Jul, 2026

Acutaas Chemicals - Quaterly Results

The Turnover for the quarter ended June 2026 of Rs. 3224.09 millions increase by 56.53% from Rs. 2059.71 millions.Net profit for the quarter ended June 2026 increased significantly by 70.00% to Rs. 758.96 millions from Rs. 446.46 millions.Operating profit for the quarter ended June 2026 rose to 1141.53 millions as compared to 670.09 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3224.09	2059.71	56.53	3224.09	2059.71	56.53	13237.92	9898.35	33.74
Other Income	44.76	160.20	-72.06	44.76	160.20	-72.06	458.78	183.36	150.21
PBIDT	1141.53	670.09	70.35	1141.53	670.09	70.35	5288.83	2434.78	117.22
Interest	11.18	6.20	80.32	11.18	6.20	80.32	30.77	58.57	-47.46
PBDT	1130.35	663.89	70.26	1130.35	663.89	70.26	5258.06	2376.21	121.28
Depreciation	90.20	74.62	20.88	90.20	74.62	20.88	330.32	240.45	37.38
PBT	1040.15	589.27	76.52	1040.15	589.27	76.52	4927.74	2135.76	130.73
TAX	281.19	142.81	96.90	281.19	142.81	96.90	1265.99	540.29	134.32
Deferred Tax	25.87	15.53	66.58	25.87	15.53	66.58	111.09	70.58	57.40
PAT	758.96	446.46	70.00	758.96	446.46	70.00	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	35.41	32.53	8.83	35.41	32.53	8.83	39.95	24.60	62.42

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Onesource Specialty - Quaterly Results

A decent increase of about 39.08% in the sales to Rs. 4464.71 millions was observed for the quarter ended June 2026. The sales figure stood at Rs. 3210.12 millions during the year-ago period.The company almost doubled its revenue to Rs. 512.25 millions from Rs. 248.15 millions in the quarter ended June 2026.Operating Profit saw a handsome growth to 1179.19 millions from 851.30 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	4464.71	3210.12	39.08	4464.71	3210.12	39.08	14053.81	12995.89	8.14
Other Income	37.87	52.55	-27.94	37.87	52.55	-27.94	150.08	176.82	-15.12
PBIDT	1179.19	851.30	38.52	1179.19	851.30	38.52	2840.01	3869.57	-26.61
Interest	305.17	270.31	12.90	305.17	270.31	12.90	1205.76	1616.50	-25.41
PBDT	874.02	580.99	50.44	874.02	580.99	50.44	1580.05	1130.57	39.76
Depreciation	361.77	332.84	8.69	361.77	332.84	8.69	1367.95	1345.12	1.70
PBT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	-214.55	-198.86
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
PAT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	200.00	6.05
Equity	114.64	114.46	0.16	114.64	114.46	0.16	114.62	114.43	0.17
PBIDTM(%)	26.41	26.52	-0.41	26.41	26.52	-0.41	20.21	29.78	-32.13

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	202 Crore
2	Syncom Formulations (India) Ltd.	1,240 Crore
3	Sigachi Industries Ltd.	991 Crore
4	Fischer Medical Ventures Ltd.	2,464 Crore
5	Morepen Laboratories Ltd.	3,101 Crore
6	Anuh Pharma Ltd.	809 Crore
7	Themis Medicare Ltd.	995 Crore
8	Gujarat Kidney And Super Speciality Ltd.	1,004 Crore
9	KMC Speciality Hospitals (India) Ltd.	2,127 Crore
10	IOL Chemicals And Pharmaceuticals Ltd.	4,453 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,629	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,551	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,586	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,145	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,983	4,73,509	41.25	5.67	23.65	14.41

About MoneyWorks4Me

*Color code for outperformance consistency

*Number is average 3 year rolling returns

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Ipca Laboratories informs about board meeting

Gland Pharma informs about board meeting

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Laurus Labs - Quaterly Results

Onesource Specialty - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Ipca Laboratories informs about board meeting

Gland Pharma informs about board meeting

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Laurus Labs - Quaterly Results

Onesource Specialty - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.